Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21441827 | 1.00 | GBA1 (0.41) | GBA1HTR1AOPRK1SPHK2SPHK1 | |
| SCHEMBL30753288 | 1.00 | GBA1 (0.41) | GBA1HTR1AOPRK1SPHK2SPHK1 | |
| SCHEMBL22443654 | 0.89 | GBA1 (0.38) | GBA1HTR1AOPRK1SPHK2SPHK1 | |
| SCHEMBL22443656 | 0.89 | GBA1 (0.38) | GBA1HTR1AOPRK1SPHK2SPHK1 | |
| SCHEMBL22444194 | 0.82 | SIGMAR1 (0.42) | GBA1HTR1ASIGMAR1ACHE | |
| SCHEMBL22444151 | 0.82 | SIGMAR1 (0.42) | GBA1HTR1ASIGMAR1ACHE | |
| SCHEMBL22443386 | 0.76 | SPHK2 (0.41) | GBA1SPHK2SPHK1SIGMAR1ACHE | |
| SCHEMBL29585107 | 0.76 | CCR3 (0.41) | OPRL1 | |
| SCHEMBL22443385 | 0.76 | SPHK2 (0.41) | GBA1SPHK2SPHK1SIGMAR1ACHE | |
| SCHEMBL960491 | 0.73 | CHRM2 (0.47) | GBA1SPHK2SPHK1SIGMAR1FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206758-A1 | SUBSTITUTED BRIDGED RING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4497751-A1 | SUBSTITUTED BRIDGED RING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Suzhou Zelgen Biopharmaceuticals Co., Ltd. (CN) | 2025-01-29 | — | — | EP | disclosed |
| CN-119317628-A | Substituted bridged ring inhibitors and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-118344386-A | Substituted bridged ring inhibitors and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2023179629-A1 | SUBSTITUTED BRIDGED RING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 苏州泽璟生物制药股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| CN-112209933-B | BTK inhibitors containing 4-azacycloheptane | 正大天晴药业集团股份有限公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-3256463-B1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2019-10-09 | — | — | EP | disclosed |
| EP-3256463-B1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2019-10-09 | — | — | EP | disclosed |
| US-10179782-B2 | Substituted sulfonamide compounds | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-10179782-B2 | Substituted sulfonamide compounds | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| EP-3256463-A1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2016128529-A1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128529-A1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179782-B2 | Substituted sulfonamide compounds | TRPA1, TRPV1, TRPV5 | GBA1 309/4885HTR1A 944/4885OPRK1 454/4885 |
| US-20250206758-A1 | SUBSTITUTED BRIDGED RING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | KRAS, WEE1, NRAS | GBA1 3915/4885HTR1A 4412/4885OPRK1 4544/4885 |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | TRPA1, TRPV1, TRPV5 | GBA1 309/4885HTR1A 944/4885OPRK1 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.